E3 ubiquitin ligases in ErbB receptor quantity control

Seminars in Cell and Developmental Biology

Volumn 21, Issue 9, 2010, Pages 936-943

  Carraway, Kermit L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Degradation; E3 ubiqutin ligase; ErbB receptor; Ubiquitination

Indexed keywords

AQUAPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; NEUREGULIN RECEPTOR DEGRADATION PROTEIN 1; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

BREAST CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

EID: 78449296171     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2010.09.006     Document Type: Review

References (113)

1. Carraway K.L.3rd. Involvement of the neuregulins and their receptors in cardiac and neural development. Bioessays 1996, 18:263-266.
2. Burden S., Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 1997, 18:847-855.
3. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007, 190:1-65.
4. Sibilia M., Kroismayr R., Lichtenberger B.M., Natarajan A., Hecking M., Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007, 75:770-787.
5. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003, 284:99-110.
6. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
7. Huang P.H., Xu A.M., White F.M. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009, 2:re6.
8. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33:369-385.
9. Saif M.W. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs 2010, 19:357-369.
10. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
11. Berger M.S., Locher G.W., Saurer S., Gullick W.J., Waterfield M.D., Groner B., et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988, 48:1238-1243.
12. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
13. Lofts F.J., Gullick WJ. c-erbB2 amplification and overexpression in human tumors. Cancer Treat Res 1992, 61:161-179.
14. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:10578-10582.
15. Hamburger A.W. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 2008, 13:225-233.
16. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
17. Campbell M.R., Amin D., Moasser M.M. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010, 23:23.
18. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L.3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994, 91:8132-8136.
19. Alimandi M., Romano A., Curia M.C., Muraro R., Fedi P., Aaronson S.A., et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10:1813-1821.
20. Sliwkowski M.X., Schaefer G., Akita R.W., Lofgren J.A., Fitzpatrick V.D., Nuijens A., et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994, 269:14661-14665.
21. Carraway K.L.3rd., Cantley L.C. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994, 78:5-8.
22. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65.
23. Soltoff S.P., Carraway K.L., Prigent S.A., Gullick W.G., Cantley L.C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994, 14:3550-3558.
24. Kim H.H., Sierke S.L., Koland J.G. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 1994, 269:24747-24755.
25. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938.
26. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
27. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
28. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
29. Liu B., Ordonez-Ercan D., Fan Z., Edgerton S.M., Yang X., Thor A.D. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882.
30. Yen L., Cao Z., Wu X., Ingalla E.R., Baron C., Young L.J., et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res 2006, 66:11279-11286.
31. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.
32. Carraway K.L., Yen Y., Ingalla E., Sweeney C. Negative regulation of signaling by the EGFR family. Cancer drug discovery and development: EGFR signaling networks in cancer therapy 2008, Humana Press, Totowa, NJ.
33. Naidu R., Yadav M., Nair S., Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998, 78:1385-1390.
34. Chuu C.P., Chen R.Y., Barkinge J.L., Ciaccio M.F., Jones R.B. Systems-level analysis of ErbB4 signaling in breast cancer: a laboratory to clinical perspective. Mol Cancer Res 2008, 6:885-891.
35. Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:259-268.
36. Kruser T.J., Wheeler D.L. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010, 316:1083-1100.
37. Fry W.H., Kotelawala L., Sweeney C., Carraway K.L. Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp Cell Res 2009, 315:697-706.
38. Hicke L., Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003, 19:141-172.
39. Mosesson Y., Mills G.B., Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008, 8:835-850.
40. Sorkin A., Goh L.K. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2009, 315:683-696.
41. Pickart C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70:503-533.
42. Mogk A., Schmidt R., Bukau B. The N-end rule pathway for regulated proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol 2007, 17:165-172.
43. Tasaki T., Kwon Y.T. The mammalian N-end rule pathway: new insights into its components and physiological roles. Trends Biochem Sci 2007, 32:520-528.
44. Cadwell K., Coscoy L. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 2005, 309:127-130.
45. Wang X., Herr R.A., Rabelink M., Hoeben R.C., Wiertz E.J., Hansen T.H. Ube2j2 ubiquitinates hydroxylated amino acids on ER-associated degradation substrates. J Cell Biol 2009, 187:655-668.
46. Mosesson Y., Shtiegman K., Katz M., Zwang Y., Vereb G., Szollosi J., et al. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 2003, 278:21323-21326.
47. Haglund K., Dikic I. Ubiquitylation and cell signaling. EMBO J 2005, 24:3353-3359.
48. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
49. Canning M., Boutell C., Parkinson J., Everett R.D. A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J Biol Chem 2004, 279:38160-38168.
50. Wu X., Yen L., Irwin L., Sweeney C., Carraway K.L. Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol Cell Biol 2004, 24:7748-7757.
51. Xu C., Kim N.G., Gumbiner B.M. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009, 8:4032-4039.
52. Snyder P.M. Down-regulating destruction: phosphorylation regulates the E3 ubiquitin ligase Nedd4-2. Sci Signal 2009, 2.
53. Meek D.W., Hupp T.R. The regulation of MDM2 by multisite phosphorylation - opportunities for molecular-based intervention to target tumours?. Semin Cancer Biol 2010, 20:19-28.
54. Parry G., Estelle M. Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Semin Cell Dev Biol 2004, 15:221-229.
55. Kerscher O., Felberbaum R., Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006, 22:159-180.
56. Hotton S.K., Callis J. Regulation of cullin RING ligases. Annu Rev Plant Biol 2008, 59:467-489.
57. Dawson T.M. Parkin and defective ubiquitination in Parkinson's disease. J Neural Transm Suppl 2006, 70:209-213.
58. Morris L.G., Veeriah S., Chan T.A. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 2010, 29:3453-3464.
59. Manfredi J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010, 24:1580-1589.
60. Boulton S.J. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006, 34:633-645.
61. Chen C., Seth A.K., Aplin A.E. Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res 2006, 4:695-707.
62. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286.
63. Krig S.R., Miller J.K., Frietze S., Beckett L.A., Neve R.M., Farnham P.J., et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 2010, 26:26.
64. Zaczek A., Welnicka-Jaskiewicz M., Bielawski K.P., Jaskiewicz J., Badzio A., Olszewski W., et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol 2008, 134:271-279.
65. Sassen A., Rochon J., Wild P., Hartmann A., Hofstaedter F., Schwarz S., et al. Cytogenetic analysis of HER1/EGFR, HER2 HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10:8.
66. Siegel P.M., Dankort D.L., Hardy W.R., Muller W.J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994, 14:7068-7077.
67. Siegel P.M., Muller W.J. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc Natl Acad Sci USA 1996, 93:8878-8883.
68. Siegel P.M., Ryan E.D., Cardiff R.D., Muller W.J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999, 18:2149-2164.
69. Miller J.K., Shattuck D.L., Ingalla E.Q., Yen L., Borowsky A.D., Young L.J., et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008, 68:8286-8294.
70. Troyer K.L., Lee D.C. Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 2001, 6:7-21.
71. Stern D.F., ERBB3/HER3 ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223.
72. Jones F.E. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:247-258.
73. De Bortoli M., Dati C. Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland. J Mammary Gland Biol Neoplasia 1997, 2:175-185.
74. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 2003, 5:461-466.
75. Huang F., Kirkpatrick D., Jiang X., Gygi S., Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 2006, 21:737-748.
76. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2:294-307.
77. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998, 12:3663-3674.
78. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999, 4:1029-1040.
79. Lill N.L., Douillard P., Awwad R.A., Ota S., Lupher M.L., Miyake S., et al. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem 2000, 275:367-377.
80. Levkowitz G., Klapper L.N., Tzahar E., Freywald A., Sela M., Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 1996, 12:1117-1125.
81. Klapper L.N., Waterman H., Sela M., Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000, 60:3384-3388.
82. Levkowitz G., Oved S., Klapper L.N., Harari D., Lavi S., Sela M., et al. c-Cbl is a suppressor of the neu oncogene. J Biol Chem 2000, 275:35532-35539.
83. Li X., Shen L., Zhang J., Su J., Liu X., Han H., et al. Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res 2007, 67:8716-8724.
84. Jansen S.M., Sleumer L.S., Damen E., Meijer I.M., van Zoelen E.J., van Leeuwen J.E. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site. Cell Signal 2009, 21:810-818.
85. Baulida J., Kraus M.H., Alimandi M., Di Fiore P.P., Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996, 271:5251-5257.
86. Cao Z., Wu X., Yen L., Sweeney C., Carraway K.L. 3rd. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 2007, 27:2180-2188.
87. Diamonti A.J., Guy P.M., Ivanof C., Wong K., Sweeney C., Carraway K.L. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc Natl Acad Sci USA 2002, 99:2866-2871.
88. Meroni G., Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 2005, 27:1147-1157.
89. Avvakumov G.V., Walker J.R., Xue S., Finerty P.J., Mackenzie F., Newman E.M., et al. Amino-terminal dimerization NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J Biol Chem 2006, 281:38061-38070.
90. Bouyain S., Leahy D.J. Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3. Protein Sci 2007, 16:654-661.
91. Qiu X.B., Goldberg A.L. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci USA 2002, 99:14843-14848.
92. Ingalla E.Q., Miller J.K., Wald J.H., Workman H.C., Kaur R.P., Yen L., et al. Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors. J Biol Chem 2010, 285:28691-28697.
93. Jackson-Fisher A.J., Bellinger G., Breindel J.L., Tavassoli F.A., Booth C.J., Duong J.K., et al. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res 2008, 10:R96.
94. Blobel C.P., Carpenter G., Freeman M. The role of protease activity in ErbB biology. Exp Cell Res 2009, 315:671-682.
95. Ni C.Y., Murphy M.P., Golde T.E., Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294:2179-2181.
96. Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia 2008, 13:235-246.
97. Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000, 275:8641-8649.
98. Rotin D., Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009, 10:398-409.
99. Scheffner M., Staub O. HECT E3s and human disease. BMC Biochem 2007, 22.
100. Rotin D. Role of the UPS in Liddle syndrome. BMC Biochem 2008, 21.
101. Omerovic J., Santangelo L., Puggioni E.M., Marrocco J., Dall'Armi C., Palumbo C., et al. The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J 2007, 21:2849-2862.
102. Feng S.M., Muraoka-Cook R.S., Hunter D., Sandahl M.A., Caskey L.S., Miyazawa K., et al. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol Cell Biol 2009, 29:892-906.
103. Li Y., Zhou Z., Alimandi M., Chen C. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 2009, 28:2948-2958.
104. Zeng F., Xu J., Harris R.C. Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J 2009, 23:1935-1945.
105. Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., Hunter D.M., et al. HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Cancer Res 2007, 67:6582-6590.
106. Young J.C., Moarefi I., Hartl F.U. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001, 154:267-273.
107. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549.
108. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
109. Murakami Y., Mizuno S., Uehara Y. Accelerated degradation of 160kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells. Biochem J 1994, 301:63-68.
110. Mimnaugh E.G., Chavany C., Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996, 271:22796-22801.
111. Xu W., Marcu M., Yuan X., Mimnaugh E., Patterson C., Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 2002, 99:12847-12852.
112. Gerbin C.S., Landgraf R. Geldanamycin selectively targets the nascent form of ERBB3 for degradation. Cell Stress Chaperones 2010, 15:529-544.
113. Zhou P., Fernandes N., Dodge I.L., Reddi A.L., Rao N., Safran H., et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003, 278:13829-13837.